

Last updated:
JULY 2019

RESEARCH OPPORTUNITIES FOR CHILDREN AND YOUNG PEOPLE WITH JIA

Juvenile idiopathic arthritis (JIA)

**There are
research studies
taking place in
your area.**

**You/your child
may be able to
take part.**

**This leaflet has information on
research studies taking place across
the United Kingdom (UK) which
children and young people with JIA
can take part in.**

**Only brief summaries are provided,
and not all inclusion and exclusion
criteria are listed. If you/your child
are interested in taking part in any
of the research studies, please speak
to your rheumatology team!**

This document can be downloaded from:
www.liverpool.ac.uk/eatc-for-children/research/workstreams/jia

OBSERVATIONAL RESEARCH STUDIES



If you are interested in a study, mention it to your rheumatology team!

Observational research studies are where researchers look at groups of people with similar health conditions or treatments and collect information about them and their condition(s).

Some studies have an acronym (e.g. BCRD). For each study, there is a description, the name of the researcher looking after the study, and a website link (if there is one).



BCRD

A study looking at how well biologics work, and the long-term safety of biologics in children.

Professor Kimme Hyrich

www.bcrdstudy.org



BSPAR- ECS

A study looking at how well etanercept works, and the long-term safety of etanercept in children.

Professor Kimme Hyrich

[www.rheumatology.org.uk/
Knowledge/Registers/Juvenile-
Idiopathic-Arthritis-register](http://www.rheumatology.org.uk/Knowledge/Registers/Juvenile-Idiopathic-Arthritis-register)



CHARMS

A large study aiming to predict how children with JIA respond to different medicines.

Professor Lucy Wedderburn

www.sparkscharms.org.uk



CLUSTER

A new collaborative project bringing together data from many JIA and JIA uveitis studies to design ways to predict treatment response and disease outcomes.

Professor Lucy Wedderburn

For more information, email
l.wedderburn@ucl.ac.uk



If you are interested in a study, mention it to your rheumatology team!

INTERVENTIONAL RESEARCH STUDIES

Interventional research studies are where people are assigned to groups that receive one or more interventions or treatments (e.g. a medicine, an exercise, an online resource), or no intervention at all. Researchers then look at the effect of the intervention or treatment on health and wellbeing.

For each study, there is a description, the locations where the study is taking place, the name of the researcher looking after the study, and a website link (if there is one).



Sarilumab in systemic JIA

BRISTOL, LEEDS
LIVERPOOL, LONDON

A study attempting to find the right dose of a new biological medicine called sarilumab in children and young people with active systemic JIA.

Professor Athimalaipet Ramanan

www.clinicaltrials.gov/ct2/show/NCT02991469



Sarilumab in polyarticular JIA

BRISTOL, LIVERPOOL,
LONDON (GOSH/UCLH)

A study attempting to find the right dose of a new biological medicine called sarilumab in children and young people with polyarticular JIA.

Professor Athimalaipet Ramanan

www.clinicaltrials.gov/show/NCT02776735



Emapalumab in MAS

LONDON (GOSH)

A study looking at how well a new biological medicine called emapalumab works in children and young people with macrophage activation syndrome (MAS), which may develop on the background of systemic JIA.

Professor Paul Brogan & Dr Despina Eleftheriou

www.clinicaltrials.gov/ct2/show/NCT03311854



Baricitinib in polyarticular JIA

BRISTOL, LONDON
(GOSH/UCLH), SHEFFIELD

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with polyarticular JIA.

Professor Athimalaipet Ramanan

www.clinicaltrials.gov/ct2/show/NCT03773965

***** THE FOLLOWING STUDIES ARE ABOUT TO OPEN. *****

REFERRALS FROM OTHER HOSPITAL CENTRES ARE WELCOMED AND WILL BE CONSIDERED!



Tofacitinib in systemic JIA

CAMBRIDGE, OXFORD

A study looking at how well tofacitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with active systemic JIA who don't respond to methotrexate.

Dr Kate Armon



Baricitinib in uveitis

BRISTOL, LIVERPOOL,
LONDON (GOSH)

A study looking at how well baricitinib, an oral Janus Kinase (JAK) inhibitor medicine, works for children and young people with JIA-associated uveitis.

Professor Athimalaipet Ramanan

INTERVENTIONAL RESEARCH STUDIES



If you are interested in a study, mention it to your rheumatology team!

***** THE FOLLOWING STUDY WILL BE OPENING IN SUMMER 2019. *****



ADJUST



ADJUST stands for 'Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial'. ADJUST will begin to identify children and young people in the UK by early summer 2019. Children and young people (2 years and older) with a diagnosis of juvenile idiopathic arthritis-associated uveitis who are currently taking adalimumab (Humira®) and are interested in stopping their medication may be eligible for this 12-month study. The hospitals which will be identifying children and young people are shown below, alongside the lead researcher(s) at each hospital.


**Professor
Athimalaipet
Ramanan**



ADJUST@ucsf.edu

**BRISTOL, LIVERPOOL, LONDON (GOSH),
NEWCASTLE, SHEFFIELD, SOUTHAMPTON**

www.clinicaltrials.gov/ct2/show/NCT03816397



Let us know what you think about our leaflet, and help us to improve it by completing our quick survey:

<http://bit.ly/2RdEcRt>